Are there any contraindications to performing an invasive dental procedure involving jaw bone manipulation in a patient receiving Enhertu (trastuzumab‑deruxtecan) who requires hematology/oncology clearance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Invasive Dental Procedure in Patient on Enhertu: Contraindications and Clearance

Enhertu (trastuzumab deruxtecan) is NOT a bone-modifying agent and does NOT carry the same risk of medication-related osteonecrosis of the jaw (MRONJ) as bisphosphonates or denosumab—therefore, invasive dental procedures with jaw bone manipulation can proceed with standard precautions after hematology/oncology clearance addresses systemic factors only.

Key Distinction: Enhertu vs. Bone-Modifying Agents

The critical issue here is drug classification. The MASCC/ISOO/ASCO guidelines 1 specifically define MRONJ risk in the context of:

  • Bone-modifying agents (BMAs): bisphosphonates and denosumab
  • Angiogenic inhibitors: bevacizumab and similar agents

Enhertu is an antibody-drug conjugate (ADC) targeting HER2 with a topoisomerase I inhibitor payload 2. It is neither a BMA nor a traditional angiogenic inhibitor. The FDA label 2 does not list MRONJ or dental complications as warnings or precautions.

What Heme/Onc Clearance Should Address

The clearance should focus on systemic safety factors from Enhertu's known toxicity profile:

1. Hematologic Parameters (Most Critical)

From the FDA label 2, common hematologic toxicities include:

  • Neutropenia: 70% all grades, 18% grade 3-4
  • Thrombocytopenia: 52% all grades, 7% grade 3-4
  • Anemia: 64% all grades, 7% grade 3-4

Acceptable pre-procedure thresholds:

  • ANC >1,500/μL (ideally >2,000/μL)
  • Platelets >50,000/μL for minor procedures, >75,000/μL for extensive bone manipulation
  • Hemoglobin >8 g/dL

2. Infection Risk Assessment

  • Check for active infections (Enhertu increases respiratory infection risk 2)
  • Ensure no febrile neutropenia (0.8% incidence 2)
  • Consider prophylactic antibiotics if ANC 1,000-1,500/μL

3. Timing Relative to Enhertu Dosing

Enhertu is dosed every 3 weeks 2. Optimal timing:

  • Schedule dental procedure 10-14 days after last Enhertu dose (nadir period passed, before next dose)
  • Allow 7-10 days healing before next Enhertu cycle if possible

4. Interstitial Lung Disease (ILD) Status

ILD occurs in 11% of patients 2. If patient has active or recent ILD:

  • Defer elective procedures
  • Coordinate with pulmonology if urgent procedure needed

No MRONJ-Specific Precautions Required

Unlike patients on denosumab 3 or bisphosphonates 1, you do NOT need:

  • Extended drug holidays (no evidence this helps with Enhertu)
  • MRONJ staging protocols
  • Specialized minimally invasive techniques beyond standard surgical principles
  • Prolonged healing observation periods specific to osteonecrosis risk

Practical Algorithm

Step 1: Verify patient is NOT on concurrent BMAs (bisphosphonates/denosumab) or high-dose steroids

  • If yes → follow MRONJ guidelines 1
  • If no → proceed to Step 2

Step 2: Obtain CBC within 7 days of procedure

  • ANC >1,500, platelets >50,000, Hgb >8 → proceed
  • Below thresholds → delay until recovery or transfuse as needed

Step 3: Confirm no active ILD or systemic infection

  • If present → defer elective procedures

Step 4: Time procedure optimally (10-14 days post-Enhertu dose)

Step 5: Use standard surgical technique with:

  • Perioperative antibiotics (standard prophylaxis, not extended courses)
  • Meticulous hemostasis
  • Primary closure when possible
  • Standard post-op care

Common Pitfalls to Avoid

  1. Conflating Enhertu with bevacizumab: While both are cancer biologics, bevacizumab (anti-VEGF) has documented MRONJ risk 1. Enhertu does not share this mechanism.

  2. Unnecessary drug holidays: The MASCC guidelines 1 note insufficient evidence even for BMA discontinuation before dental surgery. For Enhertu (not a BMA), there is zero evidence supporting discontinuation.

  3. Over-restriction of necessary dental care: Delaying medically necessary extractions in cancer patients can worsen outcomes 4. The study showed dental treatment before oncologic procedures has acceptable safety (1.6% complication rate 4).

  4. Ignoring concurrent medications: Check for actual BMAs, high-dose steroids, or other immunosuppressants that DO increase MRONJ risk 1, 5.

Documentation for Clearance

Heme/onc should document:

  • Current CBC values and acceptability
  • Timing recommendation relative to Enhertu cycle
  • ILD status
  • Any concurrent medications affecting bone/wound healing
  • Explicit statement: "Patient on Enhertu (not a BMA); standard dental surgical precautions apply"

The bottom line: Enhertu itself is not a contraindication to invasive dental procedures. Clearance should address systemic factors (counts, infection, timing) but does not require MRONJ-specific protocols.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.